Basel, 24 June 1997

Posicor approved in the United States
New cardiovascular drug for the treatment of hypertension and angina pectoris

Posicor, a new treatment for hypertension and angina pectoris has been approved by the US Food and Drug Administration. Posicor (mibefradil) is the first selective T-calcium-channel blocker and can be given once-daily for both indications hypertension and angina pectoris.

Hypertension, or high blood pressure, affects an estimated 50 million people in the United States alone. Another seven million Americans suffer from angina, a condition often characterized by recurring chest pain. Both diseaes can be linked to heart attack and death.

Posicor has already been approved for the treatment of hypertension and angina pectoris in Switzerland, the Netherlands and several countries in Latin American and Asia. In Europe, Posicor is proceeding as planned following the European mutual recognition procedure.

© 1997 F. Hoffmann-La Roche Ltd